CMC Biologics

CMC Biologics was a contract development and manufacturing organization (CDMO) founded in Copenhagen, Denmark, in 2001. The company specialized in providing integrated services for the development and manufacturing of protein-based therapeutics, such as monoclonal antibodies and other therapeutic proteins, for clients in the pharmaceutical and biotech industries.

The company's services spanned the entire drug development lifecycle, from cell line and process development to cGMP manufacturing for preclinical, clinical, and commercial use. It operated facilities in Copenhagen, Denmark, and in the U.S. in Seattle, Washington, and Berkeley, California. In 2015, Gustavo Mahler, a biopharmaceutical industry veteran with 20 years of experience, including 15 years at Bayer, became the CEO. Under his leadership, the company experienced significant growth.

In December 2016, a definitive agreement was announced for AGC Asahi Glass (AGC), a Japanese manufacturer of glass and chemicals, to acquire all shares of CMC Biologics for approximately $511 million. This acquisition was part of AGC's strategy to expand its life sciences business. Following the acquisition, in January 2018, CMC Biologics was merged with AGC Bioscience and Biomeva GmbH to form a new global CDMO named AGC Biologics. The new entity, headquartered in Bothell, Washington, combines the expertise and facilities of the merged companies to offer a broader range of services in both microbial and mammalian-based manufacturing across a global network.

Keywords: contract development manufacturing organization, CDMO, biologics manufacturing, protein-based therapeutics, monoclonal antibodies, cGMP manufacturing, cell line development, process development, biopharmaceutical services, clinical manufacturing, commercial manufacturing, microbial fermentation, mammalian cell culture, AGC Biologics, pharmaceutical services